3rd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$310,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).

LobbyistCovered position, as disclosed
SCOTT BARNES —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Health Issues HCR

Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").

LobbyistCovered position, as disclosed
SCOTT BARNES —
SAMANTHA VENTIMIGLIA —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3 (116th), S. 2543 (116th), S. 1895 (116th), H.R. 2296 (116th), H.R. 2113 (116th)

Medicare/Medicaid MMM

Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).

LobbyistCovered position, as disclosed
SCOTT BARNES —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.